Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pending Biosimilars

Executive Summary

Biosimilar applications using the 351(k) pathway under review at US FDA. Updated upon new submissions.


Related Content

Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer
Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says
Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says
US FDA's Biosimilar Advisory Committee Policy Evolves
Biologics Naming: US FDA Ponders How To Put New System In Place, While WHO Puts Hold On Pilot Study
Humira Biosimilar Interchangeability: The Race Begins
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There
Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar
Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts